221019-38-1

Upstream product

• 81228-03-7 2-phenethyloxyacetic acid 

Downstream Products

• 948894-49-3 1-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-2-phenethyloxy-ethanone 
• 948894-20-0 5-{(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-[({(3R)-1-[2-(2-phenylethoxy)ethyl]piperidin-3-yl}methyl)amino]ethyl}-8-hydroxyquinolin-2(1H)-one 
• 948894-50-6 2-[1-(2-phenethyloxy-ethyl)-piperidin-4-yl]-ethanol 
• 948894-18-6 {(3S)-1-[2-(2-phenylethoxy)ethyl]piperidin-3-yl}methanol 
• 948894-19-7 (3S)-1-[2-(2-phenylethoxy)ethyl]piperidine-3-carbaldehyde 
• 948894-17-5 (3S)-1-(2-phenethyloxy-acetyl)-piperidine-3-carboxylic acid ethyl ester 
• 958356-53-1 N-(3-cyano-pyridin-2-yl)-2-phenethyloxy-acetamide 

Relevant academic research and scientific papers

Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity

Pyrido pyrimidinones are selective agonists of the human high affinity niacin receptor GPR109A (HM74A). They show no activity on the highly homologous low affinity receptor GPR109B (HM74). Starting from a high throughput screening hit the in vitro activity of the pyrido pyrimidinones was significantly improved providing lead compounds suitable for further optimization.

Novel pyridopyprimidinone derivatives which are HM74A agonists

The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with

PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.

Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors

The present invention provides a compound of formula (1) wherein R1-R5, R25, R26, Y and X2 are defined as in claim 1. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and arc useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.